Multidimensional Healthcare Access Barriers to Prostate‐Specific Antigen Testing: A Nation‐Wide Panel Study in the United States From 2006 to 2020 DOI Creative Commons
Hari S. Iyer, Kevin H. Kensler, Charlotte Roscoe

et al.

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(21)

Published: Nov. 1, 2024

ABSTRACT Background Rising metastatic prostate cancer incidence has renewed debate regarding benefits of prostate‐specific antigen (PSA) screening. Identifying barriers to accessing screening for individuals at high risk lethal may slow this rise. We examined associations access with receipt PSA testing, stratified by sociodemographic factors. Methods pooled data from male respondents Behavior Risk Factor Surveillance Systems (BRFSS) surveys 2006 2020. Questions related affordability (insurance, cost visits) and accommodation (regular primary care provider (PCP), physician recommending a test) were considered as individual‐level barriers. For availability, we linked density the 2012 Area Health Resource File estimated driving times closest health facility within Micropolitan Metropolitan Statistical (MMSA) using Google Earth Engine. These measures used compute spatial accessibility index. fit survey‐weighted, covariate‐adjusted logistic regression models estimate past 2 years effect modification Results There 185,643 participants, whom 73% White, 11% Black, 4% Asian, Hispanic. Physician recommendation was strongest predictor having test (aOR: 14.5, 95% CI: 13.6, 15.6). Not regular PCP 0.29, 0.27, 0.31), insurance 0.64, 0.58, 0.71), prohibitive 0.82, 0.75, 0.90) associated lower testing. Access stronger predictors testing Asian White participants compared other groups ( P het < 0.004 PCP) those college education without 0.05 insurance, perceived unaffordability). Discussion regardless grouping. Future studies should consider jointly across strata.

Language: Английский

Esophageal cancer DOI Open Access

Daniel C. Eisner

JAAPA, Journal Year: 2024, Volume and Issue: 37(4), P. 19 - 24

Published: March 14, 2024

ABSTRACT Esophageal cancer is a challenging malignancy that often diagnosed in advanced stages, resulting poor prognosis. This article provides comprehensive review of the two main types esophageal cancer, squamous cell carcinoma and adenocarcinoma, reviews epidemiology, risk factors, pathogenesis, diagnostic modalities, staging systems, established emerging treatments. Recent advancements treatment for resectable unresectable also are explored. These include immunotherapy, targeted therapy, sentinel lymph node mapping, radiogenomics, palliative measures, screening measures.

Language: Английский

Citations

5
High‐throughput molecular assays for inclusion in personalised oncology trials – State‐of‐the‐art and beyond DOI Creative Commons
Anders Edsjö, Hege G. Russnes, Janne Lehtiö

et al.

Journal of Internal Medicine, Journal Year: 2024, Volume and Issue: 295(6), P. 785 - 803

Published: May 2, 2024

Abstract In the last decades, development of high‐throughput molecular assays has revolutionised cancer diagnostics, paving way for concept personalised medicine. This progress been driven by introduction such technologies through biomarker‐driven oncology trials. this review, strengths and limitations various state‐of‐the‐art sequencing technologies, including gene panel (DNA RNA), whole‐exome/whole‐genome whole‐transcriptome sequencing, are explored, focusing on their ability to identify clinically relevant biomarkers with diagnostic, prognostic and/or predictive impact. includes need assess complex biomarkers, example microsatellite instability, tumour mutation burden homologous recombination deficiency, patients suitable specific therapies, immunotherapy. Furthermore, crucial role biomarker analysis multidisciplinary boards in selecting trial inclusion is discussed relation concepts, drug repurposing. Recognising that today's exploratory techniques will evolve into tomorrow's routine diagnostics clinical study assays, importance emerging multimodal as proteomics vivo sensitivity testing, also discussed. addition, key regulatory aspects patient engagement all phases a described. Finally, we propose set recommendations consideration when planning new precision medicine trial.

Language: Английский

Citations

5
Spatial transcriptomics in cancer research and potential clinical impact: a narrative review DOI Creative Commons
Michael A. Cilento, Christopher J. Sweeney, Lisa M. Butler

et al.

Journal of Cancer Research and Clinical Oncology, Journal Year: 2024, Volume and Issue: 150(6)

Published: June 8, 2024

Spatial transcriptomics (ST) provides novel insights into the tumor microenvironment (TME). ST allows quantification and illustration of gene expression profiles in spatial context tissues, including both cancer cells which they are found. In research, has already provided metastasis, prognosis, immunotherapy responsiveness. The clinical precision oncology application next-generation sequencing (NGS) RNA profiling tumors relies on bulk methods that lack context. ability to preserve information is now possible, as it us capture heterogeneity multifocality. this narrative review, we summarize oncology, discuss clinic, review available research methods, seqFISH, MERFISH (Vizgen), CosMx SMI (NanoString), Xenium (10x), Visium Stereo-seq (STOmics), GeoMx DSP (NanoString). We then current literature with a focus solid organized by type. Finally, conclude addressing an important question: how will ultimately help patients cancer?

Language: Английский

Citations

5
Unveiling Disparities: Analyzing Hispanic Inclusion in Liver Cancer Research Databases in the United States DOI Creative Commons
Gabriela Arroyo Figueroa, Tim F. Greten, Cecilia Monge

et al.

Journal of Racial and Ethnic Health Disparities, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 23, 2024

Primary liver cancer, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma was the sixth leading cause of cancer death in United States 2023. Hispanic people constitute approximately 19% nation's total population according to US Census. patients have highest relative incidence rates compared non-Hispanic Whites Blacks, a disparity frequently overlooked research. In this study, our primary objective analyze potential underrepresentation individuals research databases. We identified databases that had cancer-specific studies be population-based States. Our search yielded 7 genomic databases, which were analyzed percentages across ethnicity race categories. study included 3104 patients; ethnic data not reported for 13.1% (n = 406) patients. Samples predominantly from who as Not (81.0%), represented 5.9%. Race follows: (61.0%), Asians (22.0%), Blacks (5.4%), Other (3.1%), Native American/American Indian/Alaska (0.4%), Pacific Islander/Native Hawaiian (0.2%) (7.9%). These findings collectively underscore significant disparities representation racial groups, particularly Hispanics. Given present demographics projected surge forthcoming years, it becomes imperative address health may worsen without efforts enhance proper inclusion

Language: Английский

Citations

2
Advanced molecular diagnostic tools: A step closer to precision medicine in neuro-oncology DOI
Elisa Aquilanti, Patrick Y. Wen

Neuro-Oncology, Journal Year: 2023, Volume and Issue: 25(10), P. 1750 - 1751

Published: July 27, 2023

Journal Article Advanced molecular diagnostic tools: A step closer to precision medicine in neuro-oncology Get access Elisa Aquilanti, Aquilanti Division of Neuro-Oncology, Department Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USADepartment Medicine, Harvard School, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Patrick Y Wen USADivision Neurology, Brigham and Women’s Hospital, Corresponding Author: Y. Wen, MD, Neuro 450 Brookline Avenue, MA 02215, ([email protected]). https://orcid.org/0000-0002-0774-7700 Volume 25, Issue 10, October 2023, Pages 1750–1751, https://doi.org/10.1093/neuonc/noad132 Published: 28 July 2023 history Corrected typeset: 19 August

Language: Английский

Citations

3
Therapeutic implementation of single-cell sequencing for dissecting colorectal cancer immune microenvironment DOI Creative Commons
Liqi Li,

Xiaoshu Zhou

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 30, 2024

Abstract Colorectal cancer (CRC) is a highly prevalent malignancy in the digestive system around globe that characterized by intricate pathogenesis, progression and poor prognosis. Recent studies indicate tumor immune microenvironment (TIME) crucial mediator of tumorigenesis with substantial diagnostic prognostic value, which complex network malignant cells, endothelial extracellular matrix, interstitial components various molecular factors. Therefore, comprehensive profiling CRC-associated TIME may substantially contribute to research on CRC pathology while accelerating pharmaceutical development for effective immunotherapy. However, tissues tend exhibit high cell heterogeneity, severely compromises accuracy data acquired through conventional sequencing methods as they are incapable discriminating different populations. Single-cell (SCS) novel technology capable comprehensively characterizating individual cells at resolution, thereby preserving heterogeneous tissue information transcriptional rare SCS technology-enabled offers emerging opportunities elucidating pathogenesis mechanisms CRC. This work provides summary unique merits potential breakthroughs context characterization, facilitate optimization intervention strategies clinics.

Language: Английский

Citations

0
Multidimensional Healthcare Access Barriers to Prostate‐Specific Antigen Testing: A Nation‐Wide Panel Study in the United States From 2006 to 2020 DOI Creative Commons
Hari S. Iyer, Kevin H. Kensler, Charlotte Roscoe

et al.

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(21)

Published: Nov. 1, 2024

ABSTRACT Background Rising metastatic prostate cancer incidence has renewed debate regarding benefits of prostate‐specific antigen (PSA) screening. Identifying barriers to accessing screening for individuals at high risk lethal may slow this rise. We examined associations access with receipt PSA testing, stratified by sociodemographic factors. Methods pooled data from male respondents Behavior Risk Factor Surveillance Systems (BRFSS) surveys 2006 2020. Questions related affordability (insurance, cost visits) and accommodation (regular primary care provider (PCP), physician recommending a test) were considered as individual‐level barriers. For availability, we linked density the 2012 Area Health Resource File estimated driving times closest health facility within Micropolitan Metropolitan Statistical (MMSA) using Google Earth Engine. These measures used compute spatial accessibility index. fit survey‐weighted, covariate‐adjusted logistic regression models estimate past 2 years effect modification Results There 185,643 participants, whom 73% White, 11% Black, 4% Asian, Hispanic. Physician recommendation was strongest predictor having test (aOR: 14.5, 95% CI: 13.6, 15.6). Not regular PCP 0.29, 0.27, 0.31), insurance 0.64, 0.58, 0.71), prohibitive 0.82, 0.75, 0.90) associated lower testing. Access stronger predictors testing Asian White participants compared other groups ( P het < 0.004 PCP) those college education without 0.05 insurance, perceived unaffordability). Discussion regardless grouping. Future studies should consider jointly across strata.

Language: Английский

Citations

0